Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading IMUC News...
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.76% | 172.50 | 1.1% | $711.75m | |
| GILD | Gilead Sciences, Inc. | 0.09% | 70.54 | 0.9% | $695.99m | |
| CELG | Celgene Corporation | 0.47% | 134.31 | 1.1% | $649.60m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.75% | 517.33 | 2.7% | $572.31m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.13% | 126.07 | 1.9% | $521.18m | |
| BIIB | Biogen Inc. | -0.09% | 280.32 | 1.2% | $500.23m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.50% | 133.50 | 1.9% | $279.31m | |
| INCY | Incyte Corporation | 0.48% | 136.28 | 2.6% | $278.87m | |
| CLVS | Clovis Oncology, Inc. | -1.84% | 95.00 | 18.0% | $249.90m | |
| TSRO | TESARO, Inc. | -2.16% | 146.53 | 14.7% | $249.01m | |
| ILMN | Illumina, Inc. | 1.25% | 185.28 | 3.5% | $164.61m | |
| BLUE | Bluebird Bio, Inc. | -5.49% | 112.00 | 19.3% | $162.00m | |
| PBYI | Puma Biotechnology, Inc. | 1.22% | 87.50 | 21.1% | $145.68m | |
| KITE | Kite Pharma, Inc. | 7.09% | 100.66 | 16.1% | $139.56m | |
| EXAS | Exact Sciences Corporation | 2.31% | 35.51 | 26.3% | $130.55m |
Company Profile
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.,0087QL-E